April 26, 2018 2:34 PM ET


Company Overview of Biological E. Limited

Company Overview

Biological E. Limited operates as a biological products company that develops, manufactures, markets, and supplies preventive medicines, vaccines, and pharmaceutical products. It offers immunization vaccines; active pharmaceutical ingredients; and anti infective, anticoagulants, analgesics and antipyretic, gastrointestinal therapy, nutraceuticals, and respiratory therapy products, as well as sera and other biological products. Biological E. Limited was formerly known as Biological Products Private Limited. The company was founded in 1953 and is based in Hyderabad, India.

18/1&3, Azamabad

Hyderabad,  500 020


Founded in 1953


91 40 3021 3999


91 40 2761 5309

Key Executives for Biological E. Limited

MD & Director
Chief Operating Officer
Age: 64
Senior Vice President of Quality
Senior Vice President of Technical Operations
Senior Vice President of Development
Compensation as of Fiscal Year 2017.

Biological E. Limited Key Developments

Biological E. Limited Presents at BioPharma India Convention 2017, Sep-19-2017

Biological E. Limited Presents at BioPharma India Convention 2017, Sep-19-2017. Venue: GRAND HYATT MUMBAI, MUMBAI, Maharashtra, India. Presentation Date & Speakers: Sep-19-2017, Akshay Goel, Senior VP Technical Development. Sep-20-2017, Akshay Goel, Senior VP Technical Development.

Takeda Pharmaceutical Company Limited and Biological E. Limited Announces Partnership to Develop Low-Cost Combination Vaccines for Low- and Middle-Income Countries Around the Globe

Takeda Pharmaceutical Company Limited and Biological E. Limited announced that they have entered into a collaboration whereby two licensing agreements to expedite the development and delivery of affordable combination vaccines have been executed. BE will commercialize the vaccine in India, China and low- and middle-income countries where large, unmet public health needs exist. Takeda has sold both the measles and pertussis vaccines in the Japanese market for more than 20 years. In heavily populated countries like India, where 25.7 million births occurred in 2015, substantial opportunities remain to deliver critical vaccines to those who need them. In the absence of access to vaccines in many parts of the world, this partnership illustrates Takeda’s desire to forge the kind of collaborations needed to overcome this public health challenge in low- and middle-income countries. Under these agreements, Takeda will conduct a transfer from Japan to BE its existing measles and acellular pertussis vaccine bulk production technology, including the provision of technical services such as support in infrastructure review, training for production and quality control, technical assistance in process development, preclinical study design and production of clinical batch and the first commercial batches. BE will scale up the bulk production technology transferred from Takeda and will be solely responsible for conducting and funding development activities for the combination vaccines. BE has rights to use Takeda’s measles vaccine technology for a combination MR. vaccine and the right to use Takeda’s pertussis vaccine technology for any pertussis-containing combination vaccine. BE will have commercialization rights for the MR. and pertussis vaccines in India, China and selected public markets worldwide as defined in the agreements.

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Biological E. Limited, please visit www.biologicale.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.